The need for spirometry before physicians can write an Afrezza prescription has been cited by analysts as an impediment to broader use of the inhaled insulin. Rarely does a new therapy generate as ...

Afrezza (insulin human) is prescribed to manage blood sugar levels in adults with diabetes. The drug can cause side effects that range from mild to serious. Examples include low blood sugar levels and ...

Paris and Valencia, Calif. – February 3, 2015 – Sanofi and MannKind Corporation announced today that Afrezza ® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by ...

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

The CEO said the changes will finally allow the company to set the inhaled insulin apart from its rivals. FDA has granted MannKind Corp. a label change for the inhaled mealtime insulin, Afrezza, that ...

Forbes contributors publish independent expert analyses and insights. I write about the science behind healthcare companies. Unfortunately, the article was completely lacking in any specific ...

PARIS and VALENCIA, Calif., Aug. 11, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive ...

When Sanofi announced it was returning the marketing rights for inhaled insulin Afrezza in January, doubts were cast on the future of MannKind Corp, the maker of the drug. Since then, the key question ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive six ...

For a drug that many hoped would reach blockbuster status, MannKind Corporation's inhaled insulin Afrezza is off to an awful start. The promise and potential of this medication continues to look huge, ...